ELAN
Price
$21.27
Change
-$0.03 (-0.14%)
Updated
Dec 11 closing price
Capitalization
10.57B
75 days until earnings call
Intraday BUY SELL Signals
EVO
Price
$3.07
Change
+$0.07 (+2.33%)
Updated
Dec 11 closing price
Capitalization
1.09B
110 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ELAN vs EVO

Header iconELAN vs EVO Comparison
Open Charts ELAN vs EVOBanner chart's image
Elanco Animal Health
Price$21.27
Change-$0.03 (-0.14%)
Volume$4.2M
Capitalization10.57B
Evotec SE
Price$3.07
Change+$0.07 (+2.33%)
Volume$151.56K
Capitalization1.09B
ELAN vs EVO Comparison Chart in %
ELAN
Daily Signal:
Gain/Loss:
EVO
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ELAN vs. EVO commentary
Dec 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and EVO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 13, 2025
Stock price -- (ELAN: $21.27 vs. EVO: $3.07)
Brand notoriety: ELAN: Notable vs. EVO: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 78% vs. EVO: 192%
Market capitalization -- ELAN: $10.57B vs. EVO: $1.09B
ELAN [@Pharmaceuticals: Generic] is valued at $10.57B. EVO’s [@Pharmaceuticals: Generic] market capitalization is $1.09B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.29B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 1 FA rating(s) are green whileEVO’s FA Score has 1 green FA rating(s).

  • ELAN’s FA Score: 1 green, 4 red.
  • EVO’s FA Score: 1 green, 4 red.
According to our system of comparison, ELAN is a better buy in the long-term than EVO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 5 TA indicator(s) are bullish while EVO’s TA Score has 4 bullish TA indicator(s).

  • ELAN’s TA Score: 5 bullish, 4 bearish.
  • EVO’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ELAN is a better buy in the short-term than EVO.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а -3.27% price change this week, while EVO (@Pharmaceuticals: Generic) price change was -4.95% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.50%. For the same industry, the average monthly price growth was -1.01%, and the average quarterly price growth was +19.25%.

Reported Earning Dates

ELAN is expected to report earnings on Feb 25, 2026.

EVO is expected to report earnings on Apr 01, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.50% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ELAN($10.6B) has a higher market cap than EVO($1.09B). ELAN YTD gains are higher at: 75.640 vs. EVO (-26.202). ELAN has higher annual earnings (EBITDA): 1.45B vs. EVO (-121.33M). ELAN has more cash in the bank: 539M vs. EVO (356M). EVO has less debt than ELAN: EVO (107M) vs ELAN (4.21B). ELAN has higher revenues than EVO: ELAN (4.48B) vs EVO (777M).
ELANEVOELAN / EVO
Capitalization10.6B1.09B975%
EBITDA1.45B-121.33M-1,194%
Gain YTD75.640-26.202-289%
P/E Ratio303.86N/A-
Revenue4.48B777M577%
Total Cash539M356M151%
Total Debt4.21B107M3,934%
FUNDAMENTALS RATINGS
ELAN vs EVO: Fundamental Ratings
ELAN
EVO
OUTLOOK RATING
1..100
5677
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
92
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
7894
PRICE GROWTH RATING
1..100
4364
P/E GROWTH RATING
1..100
22
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EVO's Valuation (92) in the null industry is in the same range as ELAN (94) in the Agricultural Commodities Or Milling industry. This means that EVO’s stock grew similarly to ELAN’s over the last 12 months.

EVO's Profit vs Risk Rating (100) in the null industry is in the same range as ELAN (100) in the Agricultural Commodities Or Milling industry. This means that EVO’s stock grew similarly to ELAN’s over the last 12 months.

ELAN's SMR Rating (78) in the Agricultural Commodities Or Milling industry is in the same range as EVO (94) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

ELAN's Price Growth Rating (43) in the Agricultural Commodities Or Milling industry is in the same range as EVO (64) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

ELAN's P/E Growth Rating (2) in the Agricultural Commodities Or Milling industry is in the same range as EVO (2) in the null industry. This means that ELAN’s stock grew similarly to EVO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANEVO
RSI
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 2 days ago
66%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
59%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
Bearish Trend 3 days ago
76%
Bearish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
74%
Bullish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
73%
Bearish Trend 2 days ago
76%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 2 days ago
62%
Advances
ODDS (%)
Bullish Trend 18 days ago
65%
Bullish Trend 2 days ago
68%
Declines
ODDS (%)
Bearish Trend 4 days ago
72%
Bearish Trend 4 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
70%
Bearish Trend 2 days ago
70%
Aroon
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 2 days ago
64%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signal:
Gain/Loss:
EVO
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
JDVI35.730.53
+1.51%
JHancock Discp Val Intl Sel ETF
NBCR31.930.05
+0.16%
Neuberger Berman Core Equity ETF
VTEI100.670.08
+0.08%
Vanguard Intermediate-Term Tx-Exm Bd ETF
AMDG31.91-0.08
-0.25%
Leverage Shares 2X Long AMD Daily ETF
MVT10.76-0.04
-0.37%
Blackrock Munivest Fund II

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
-0.14%
VTRS - ELAN
49%
Loosely correlated
-0.09%
ZTS - ELAN
45%
Loosely correlated
-0.35%
PAHC - ELAN
42%
Loosely correlated
+2.23%
SNDL - ELAN
39%
Loosely correlated
+4.12%
AMPH - ELAN
38%
Loosely correlated
+0.74%
More

EVO and

Correlation & Price change

A.I.dvisor indicates that over the last year, EVO has been loosely correlated with SNDL. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if EVO jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EVO
1D Price
Change %
EVO100%
+2.33%
SNDL - EVO
42%
Loosely correlated
+4.12%
PRGO - EVO
27%
Poorly correlated
-0.67%
ACET - EVO
26%
Poorly correlated
-5.81%
ELAN - EVO
25%
Poorly correlated
-0.14%
OGI - EVO
24%
Poorly correlated
-1.80%
More